Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026)
Assembly Biosciences' (ASMB) quarterly Income from Continuing Operations came in at 11697000.0 in Q1 2026, down 17.17% year-on-year from 14121556.54 in Q1 2025, and down 152.95% quarter-over-quarter from 22090000.0 in Q4 2025.
Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Assembly Biosciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 11697000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 17.17% year-over-year to 11697000.0 in Q1 2026; TTM through Mar 2026 was 9001000.0, a 78.09% increase from a year earlier, with the FY2025 full-year figure at 6122000.0, up 84.76% from the prior year.
- Income from Continuing Operations fell to 11697000.0 in Q1 2026 per ASMB's latest filing, from 22090000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 22090000.0 in Q4 2025 and bottomed at 24704000.0 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 11152000.0 (2024), against an average of 12718941.18.
- Across the five-year window, Income from Continuing Operations jumped 313.74% in 2025 and dropped 17.17% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 24154000.0 in 2022, then soared by 54.62% to 10962000.0 in 2023, then rose by 5.72% to 10335000.0 in 2024, then jumped by 313.74% to 22090000.0 in 2025, then plunged by 152.95% to 11697000.0 in 2026.
- Per Business Quant, the three latest ASMB Income from Continuing Operations figures stand at 11697000.0 (Q1 2026), 22090000.0 (Q4 2025), and 9196000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Assembly Biosciences | 431.63 Mn | 205.03 Mn | - | -11.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.70 Mn |
| Dec 31, 2025 | 22.09 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -10.20 Mn |
| Mar 31, 2025 | -9.98 Mn |
| Dec 31, 2024 | -10.34 Mn |
| Sep 30, 2024 | -9.61 Mn |
| Jun 30, 2024 | -11.15 Mn |
| Mar 31, 2024 | -9.08 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -14.42 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -19.27 Mn |
| Dec 31, 2022 | -24.15 Mn |
| Sep 30, 2022 | -23.40 Mn |
| Jun 30, 2022 | -24.70 Mn |
| Mar 31, 2022 | -23.25 Mn |
| Dec 31, 2021 | -63.72 Mn |
| Sep 30, 2021 | -26.96 Mn |
| Jun 30, 2021 | -24.62 Mn |